Amplíe su conocimiento

Learn more about external studies conducted on some of our key technologies and assays, including platelet function analysis, P2Y12 testing*, D-dimer testing, LOCI technology, and preanalytical variables in coagulation testing.

Evaluation of the automated coagulation analyzer CS-5100 and its utility in high throughput laboratories

Clin Chem Lab Med. 2014 Apr; Advance online publication. doi: 10.1515/cclm-2013-1094


A practical concept for preoperative identification of patients with impaired primary hemostasis.
Clin Appl Thromb Hemost. 2004 Jul;10(3):195-204.

 

A practical concept for preoperative management of patients with impaired primary hemostasis.
Clin Appl Thromb Hemost. 2004 Apr;10(2):155-66.


Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases.
Blood. 1998 Feb;91(4):1325-1331.

Clinical utility of the PFA-100.
Semin Thromb Hemost. 2008 Nov;34(8):709-33.

Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS.
J Thromb Haemost. 2006 Sep;4:1-6.

Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.
Circulation. 2009 Dec 22;120(25):2586-97.


The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y12 receptor inhibition.
Platelets. 2011;22(1):19-25.

Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.

JAMA. 2011 Jun 1;305(21):2174.


Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients.
J Thromb Haemost. 2007;5:1115–1124.

Novel gain-of-function mutations of platelet glycoprotein Iba by valine mutagenesis in the Cys209-Cys248 disulfide loop.
J Biol Chem. 2000;275:27663-70.

The diagnosis, evaluation, and management of von Willebrand disease. NHLBI VWD Expert Panel.
NIH Publication No. 08-5833, 2008.

Laboratory diagnosis of von Willebrand disease.
Hämostaseologie. 2010;30:203–206.


A multicenter evaluation of a new quantitative highly sensitive D-dimer assay for exclusion of venous thromboembolism.
Thromb Haemost. 2008;100:505–512.

Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer.
Clin Chem. 2008;54:2042-2048.

Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study.
Haematologica. 2008 June;93(6):900-907.

The diagnostic management of acute venous thromboembolism during pregnancy: recent advancements and unresolved issues.
Thrombosis Research. 2011;127(Suppl. 3):S13-S16.

An age-adapted approach for the use of D-dimers in the exclusion of deep venous thrombosis.
Am J Hematol. 2009;84:488-491.

D-Dimer for venous thromboembolism diagnosis: 20 years later.
J Thromb Haemost. 2008;6(7):1059-71.

D-dimer assays in diagnosis and management of thrombotic and bleeding disorders.
Semin Thromb Hemost. 2012;38(7):673-82.

The diagnosis and treatment of venous thromboembolism.
Hematology Am Soc Hematol Educ Program. 2013;2013:457-63.

D-dimer testing in laboratory practice.
Clin Chem. 2011;57(9):1256-62.

Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study.
JAMA. 2014;311(11):1117-24.

The combination of four different clinical decision rules and an age-adjusted D-dimer cut-off increases the number of patients in whom acute pulmonary embolism can safely be excluded.
Thromb Haemost. 2012;107(1):167-71.

D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study.
Blood. 2014;124(2):196-203.

Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests.
Thromb Haemost. 2014;112(5).

Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses.
PLoS One. 2013;8(2):e55175.

Hypercoagulability, D-dimer and atrial fibrillation: an overview of biological and clinical evidence.
Ann Med. 2014:1-8.

Meta-analysis of usefulness of d-dimer to diagnose acute aortic dissection.
Am J Cardiol. 2011;107(8):1227-34.

D-Dimer levels at different stages of pregnancy in Australian women: a single center study using two different immunoturbidimetric assays.
Thromb Res. 2012;130(3):e171-7.

D-dimer in preeclampsia: systematic review and meta-analysis.
Clin Chim Acta. 2012;414:166-70.

The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview.
J Thromb Haemost. 2007;5(3):604-6.

Evaluation of the Innovance d-dimer assay for the diagnosis of disseminated intravascular coagulopathy in different clinical settings.
Clin Appl Thromb Hemost. 2014;20(1):91-7.


ProC® Global: a functional screening test that predicts recurrent venous thromboembolism.
Thromb Haemost. 2005;93:600-4.

Laboratory methods in the haemostatic laboratory.
Thromb Haemost. 2006;96:545-6.

Evaluation of ProC® Global assay in women with a history of venous thromboembolism on hormonal therapy.
Thromb Haemost. 2006;96:578-83.

Modification of the ProC® Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation.
Blood Coagul Fibrinolysis. 2001;12:569-576.


Clinical multicenter evaluation of a new FXa-based Antithrombin assay.
Int J Lab Hematol. 2011 Oct;33(5):498-506.


Immunoassays for diagnosis of coagulation disorders.
Hämostaseologie. 2010 Apr.

Coagulation assays based on the Luminescent Oxygen Channeling Immunoassay technology.
Clin Chem Lab Med. 2011;49(5):855-860.

Luminescent oxygen channeling assay (LOCITM): sensitive, broadly applicable homogenous immunoassay method.

Clin Chem. 1996;42(9):1518-1526.


Errors in laboratory medicine.
Clin Chem. 2002;48(5):691-698.

Preanalytic error tracking in a laboratory medicine department: results of a 1-year experience.
Clin Chem. 2006;52(7):1442-3.

Preanalytical and postanalytical variables: the leading causes of diagnostic errors in hemostasis?
Sem Thromb Hemost. 2008;34(37):612-634.

Mistakes in a stat laboratory: types and frequency.
Clin Chem. 1997;43(8):1348-1351.

Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays and molecular hemostasis assays.
CLSI Guidelines. Approved Guideline-Fifth Edition; H21-A5.